Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5 þ B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malignant cells due to decreased apoptosis. CD84 belongs to the signaling lymphocyte activating molecule family of immunoreceptors, and has an unknown function in CLL cells. Here, we show that the expression of CD84 is significantly elevated from the early stages of the disease, and is regulated by macrophage migration inhibitory factor and its receptor, CD74. Activation of cell surface CD84 initiates a signaling cascade that enhances CLL cell survival. Both downmodulation of CD84 expression and its immune-mediated blockade induce cell death in vitro and in vivo. In addition, analysis of samples derived from an on-going clinical trial, in which human subjects were treated with humanized anti-CD74 (milatuzumab), shows a decrease in CD84 messenger RNA and protein levels in milatuzumab-treated cells. This downregulation was correlated with reduction of Bcl-2 and Mcl-1 expression. Thus, our data show that overexpression of CD84 in CLL is an important survival mechanism that appears to be an early event in the pathogenesis of the disease. These findings suggest novel therapeutic strategies based on the blockade of this CD84-dependent survival pathway.
INTRODUCTION

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and is characterized by the progressive accumulation of small mature CD5
þ lymphocytes in the peripheral blood, lymphoid organs and bone marrow (BM). The main feature of the disease is decreased apoptosis, resulting in the pathologic accumulation of these malignant cells. 1 Despite major progress in the last few years in the understanding of the biology and pathophysiology of this disease, as well as the development of better treatment modalities, CLL remains incurable in most patients, and even control of the disease requires aggressive treatment with significant side effects. CD74 is a type-II integral membrane protein that was originally thought to function mainly as an major histocompatibility complex class-II chaperone. 2 It was shown previously that macrophage migration inhibitory factor (MIF) binds to the CD74 extracellular domain, a process that results in regulating survival of mature murine B cells. [3] [4] [5] [6] [7] [8] In CLL, CD74 and its ligand MIF were shown to regulate survival of the leukemic cells. Binding of MIF to CD74 initiates a signaling cascade that can be observed from the very early stages of the disease. This pathway induces nuclear factor-kB activation, resulting in the upregulation of Bcl-2, which in turn promotes cell survival. [9] [10] [11] Blocking of this pathway by the monoclonal anti-CD74 antibody (mAb) hLL1 (milatuzumab) 12 leads to decreased cell survival. 9, 10 To determine the identities of the molecules whose expression is modulated by CD74, thereby regulating CLL survival, we investigated CD74 target genes. One striking example that we identified (see Results), whose expression was strongly regulated by CD74, is CD84.
CD84 is a member of the signaling lymphocyte activation molecule (SLAM) immunoglobulin superfamily. It is a singlechain cell-surface protein with a cytoplasmic tail that contains four tyrosines. 13 CD84 strongly self-associates 14, 15 with a Kd in the submicromolar range; the association is driven by the Ig-V domain, forming an orthogonal homophilic dimer. 16 The SLAM family was found to modulate the behavior of immune cells. [17] [18] [19] [20] This seems to be due to the capacity of these receptors to interact with SLAM-associated protein (SAP)-related molecules, a group of SRC homology 2 (SH2) domain adapters. The SAP family is comprised of three members: SAP, Ewing's sarcoma-associated transcript-2 (EAT-2), and in rodents, EAT-2-related transducer (ERT). 18, 21 In humans, the gene encoding ERT has evolved into a non-functional pseudo-gene. SAP does not appear to be expressed in B cells; rather EAT-2 is proposed as the functional homolog in these cells. 22, 23 The interaction of the SLAM family receptors with SAP family members is mediated by tyrosine-based motifs in the cytoplasmic region of SLAM-related receptors, and by the SH2 domain of SAP-related adapters. 23 Although CD84 was originally cloned from a human B-cell line complementary DNA library, very little is known regarding its biology. It was shown recently that CD84 is required for prolonged T cell-B cell contact and for optimal T follicular helper function and germinal center formation. 24 Nevertheless, both the expression and the function of CD84 in the biology of malignant B cells remain to be fully explored.
In the current study, we examined the expression and function of CD84 in CLL cells. Our results show an elevation of CD84 expression in CLL cells from early disease stages in a MIF-CD74-dependent manner. CD84 expression in turn regulates the survival of CLL cells in vitro and in vivo. Thus, blocking CD84 activity may be a novel therapeutic strategy for interfering with tumorigenic survival pathways.
RESULTS
CD84 expression is elevated in CLL cells in a MIF/CD74-dependent manner To better understand the biological function of CD74 in CLL cells, we sought to identify target genes induced by CD74 activation. Thus, CLL cells were incubated in the presence or absence of the CD74 ligand, MIF (100 ng/ml), for 18 h, and RNA from MIF-stimulated cells was compared with RNA derived from unstimulated cells using the Affymetrix GeneChip expression analysis system (GSE37430). Many genes were found to be differentially expressed in these populations; one example was CD84, whose expression was markedly elevated in the MIFinduced CLL cells.
As the expression of CD84 was not characterized previously in CLL, we next determined its expression levels in CLL cells from patients at various disease stages. Purified B cells from healthy subjects as well as early-and advanced-stage CLL cells were analyzed for the presence of CD84 messenger RNA (mRNA; targeting a segment common to all isoforms). As shown in Figures  1a and b , low levels of CD84 message were detected in normal B cells, whereas elevated levels of CD84 mRNA were observed in all the CLL patients, regardless of the stage of disease (Supplementary Table 3 ). Genomic characterization of CD84 revealed the existence of five isoforms differing in their cytoplasmic domains. 25 Isoform c was the dominant isoform expressed in CLL cells (data not shown).
We next compared by flow cytometry the cell surface expression levels of CD84 in normal and CLL cells. CD84 cell surface levels were significantly higher in all CLL cells when compared with total ( Figure 1c Table 3 ). To verify that CD84 expression is indeed modulated by CD74 and its ligand, MIF, we analyzed its mRNA levels in MIF-stimulated and unstimulated normal ( Figure 2a ) and CLL (Figures 2b and c;  Supplementary Table 4) cells. MIF stimulation elevated CD84 mRNA levels in both normal and CLL cells. Hematopoietic cells express multiple SLAM family receptors, which are all located at a restricted chromosomal region. We then wished to determine whether expression of other members of the SLAM family is also elevated following MIF stimulation. As shown in Supplementary Figure 1B , CD84 mRNA levels were elevated in most patients analyzed, whereas the elevation of other members of the SLAM family was not consistent. Thus, CD84 is the SLAM member whose expression is most universally regulated by MIF. The elevation in CD84 mRNA resulted in a significant increase in CD84 cell surface expression on CLL cells, which are already high on these cells ( Figure 2d percent and MFI; Supplementary Figure 2C and Supplementary Table 4) .
ISO-1 is a non-toxic inhibitor of MIF that binds to bioactive MIF at its N-terminal tautomerase site and interferes with its biologic activity. 26 Blocking MIF by ISO-1 downregulated the MIF-induced increase in CD84 mRNA levels and cell surface expression levels (Supplementary Figure 2) , further demonstrating that MIF regulates CD84 expression levels. In addition, blocking CD74 using the humanized anti-CD74 blocking antibody (hLL1) specifically downregulated the ligand-induced CD84 mRNA levels (Figure 2e ), whereas hLL1 had no effect on CD84 expression in cells incubated in the absence of MIF (data not shown). Thus, MIF binding to its CD74 receptor induces a signaling cascade that upregulates CD84 expression in CLL cells.
Activation of cell surface CD84 in CLL cells initiates a survival cascade To characterize the signaling cascade induced by CD84 in CLL cells, CD84 was directly activated by an agonistic anti-CD84 mAb. 22 The cells then were washed, and bound mAb was crosslinked with F(ab') 2 goat anti-mouse Ig. It was previously shown that B cells do not express SAP. 27 In our hands, as well, SAP expression could not be detected at the mRNA level in CLL cells. We therefore followed EAT-2 expression and function. EAT-2 mRNA was previously shown to be expressed in B cells. 18, 28 EAT-2 message and protein were expressed in normal peripheral B cells as well as in CLL cells (Supplementary Figure 3A) . EAT-2 binds with high affinity to a phosphorylated motif present in the cytoplasmic region of the SLAM family of receptors via its SH2 domain. 28 In CLL cells, EAT-2 phosphorylation was augmented following CD84 stimulation (Figure 3a) .
EAT-2 was demonstrated to directly bind to the catalytic domain of Src family kinases. 29 We therefore analyzed the association of various members of the Src family with EAT-2 following CD84 activation. As shown in Figure 3b , higher levels of Lck were pulled-down by EAT-2 following stimulation of CD84, whereas there was no change in Fyn or Src binding (Supplementary Figures 3B-D) . Thus, activation of CD84 results in augmented specific binding of Lck to EAT-2. Finally, increased Akt phosphorylation was detected following CD84 stimulation, Figure 3F) .
We next wished to determine whether the CD84-induced cascade regulates CLL survival. Cells were incubated in the presence or absence of the activating anti-CD84, and the mRNA levels of the anti-apoptotic genes, Bcl-2 and Mcl-1, were analyzed. CD84 stimulation specifically elevated Bcl-2 and Mcl-1 mRNA (Figures 4a and b; Supplementary Table 5) . As a more significant elevation in Bcl-2 message was detected, we continued analyzing the effect of CD84 stimulation on Bcl-2 protein levels. As shown in Figure 4c , following CD84 stimulation, there was a significant elevation in Bcl-2 protein levels (Supplementary Table 5 ). These results suggest that activation of CD84 initiates a survival cascade. We then followed CLL survival following CD84 stimulation by Annexin propidium iodide (PI) staining ( Figure 4d ) and by analysis of caspase 3 and 7 activity by Magic Red staining (Figure 4e ). CD84 stimulation specifically reduced the Annexin/Magic Redpositive populations, showing that CD84 activation augments CLL survival. To directly demonstrate the role of CD84 in cell survival, a human CD84 isoform c myc construct (CD84-full; Supplementary Figure 4A ) was transfected to HEK-293 cells, which were previously shown to transmit a similar CD74-dependent survival cascade 9 and which express low levels of endogenous CD84 (Supplementary Figure 4B-D) . Expression of CD84 and its downstream cascade were then followed. CD84 cell surface expression levels were significantly elevated in transfected HEK-293 cells (Supplementary Figure 4B) . Overexpression of hCD84 elevated Bcl-2 mRNA (Supplementary Figure 4C) and protein (Supplementary Figure 4D ) levels in the transfected cells. In order to further dissect the mechanism of action of CD84 that results in induction of cell survival, we wished to determine the role of the tyrosine residues in the CD84 intra-cytoplasmic domain. The cytoplasmic tail of CD84c contains four tyrosine motifs (Y262, Y279, Y299, Y324). Two of them (Y262 and Y299) were characterized as consensus motifs for SH2-interactions with SAP/EAT2. 22, 28 Little is known about the other two SH2-interacting motifs (Y279 and Y324), besides the resemblance of Y324 to an ITIM motif. 31 Thus, two different tyrosine substituted mutants were generated, one with Y262F and Y299F (A2), and the other with the Y279F and Y324F mutations (B2).
To determine which motifs regulate Bcl-2 expression, HEK-293 cells were transiently transfected with native hCD84, the two different tyrosine substituted CD84 mutants (A2, B2), or empty vector as a control. After 6 h, the cells were stimulated with the activating anti-CD84 antibody (152-1D5) or control antibody. The cells were then harvested; expression of the constructs was verified by probing for the myc-tagged recognition sequence (not shown), and the Bcl-2 mRNA (Supplementary Figure 4E) and protein (Supplementary Figure 4F ) levels were analyzed. Transfection of hCD84 elevated Bcl-2 expression. Moreover, hCD84 ligation with agonistic anti-CD84 antibody further upregulated the levels of Bcl-2 mRNA (Supplementary Figure 4E) and protein (Supplementary Figure 4F) . However, CD84-induced elevation of Bcl-2 mRNA was not observed in the HEK-293 cells transfected with either the A2-or the B2-mutated constructs. Thus, both pairs of tyrosine residues are essential for the CD84-induced survival cascade.
To directly show that CD84 induces CLL survival in a Bcl-2-dependent manner, CD84 levels were downregulated using si-CD84 knockdown, and Bcl-2 mRNA levels were determined. As shown in Figure 4f , reduced levels of CD84 resulted in significantly lower levels of Bcl-2 message. Then, to directly determine the role of Bcl-2 in the CD84-induced cascade, Bcl-2 expression levels were reduced by si-Bcl-2 knockdown, and cell survival following CD84 CD84 is a survival receptor I Binsky-Ehrenreich et al stimulation was analyzed. The elevation in cell survival observed following CD84 stimulation was significantly reduced (Figure 4g ) in cells whose Bcl-2 levels were downregulated (Supplementary Figure 4G) . We did not observe a complete block in the survival response induced by CD84, probably because the reduction in Bcl-2 expression was partial, and because other survival proteins, such as Mcl-1, are involved in this survival cascade, as well. These findings were further confirmed using an additional agonistic antibody, derived from the anti-CD84 agonistic hybridoma, D1-300, that was generated against the CD84 extracellular domain (Figure 5a ; Supplementary Figure 5A ; Materials and methods). This stimulation resulted in a similar elevation of Bcl-2 mRNA levels (Supplementary Figure 5B) and cell survival (Supplementary Figure 5C) . Together, these results show that CD84 functions as a survival receptor on CLL cells, and its activation initiates a cascade that regulates CLL survival.
Blocking the homophilic interaction of cell surface CD84 results in apoptosis of CLL cells CD84 function was shown previously to be regulated by cell-cell contacts and homophilic interactions. 32 We therefore hypothesized that these interactions could be inhibited using a truncated CD84 fragment that can bind to CD84, thereby blocking the ability of the receptor to engage in further interactions. Thus, a myc/his6-tagged CD84 construct was generated, expressing the CD84 extracellular domain, without its membrane and cytosolic regions (CD84-ECD; Figure 5a ) and purified as described in Materials and methods. The purified molecule was detected by western blot analysis as a prominent band between 43 and 50 kDa (Supplementary Figure 5A) . We determined whether CD84-ECD could inhibit the CD84-induced survival cascade in CLL cells. ECD-CD84 was then added to CLL cells, and Bcl-2 levels, Mcl-1 levels and cell survival were measured. Incubation with ECD-CD84 specifically downregulated Bcl-2 (Figures 5b and c) and Mcl-1 (Figure 5d ) mRNA levels, and inhibited cell survival (Figure 5e ). Thus, homophilic interactions regulate CLL survival; interfering with these CD84 interactions induces cell death.
We next determined whether blocking CD84 activity with inhibitory antibodies similarly induces cell death. CLL cells were incubated with supernatant derived from an antagonistic hybridoma (F8) that recognizes CD84-ECD (Materials and methods), and survival was followed over time. Supernatant derived from hybridoma F8 reduced Bcl-2 and Mcl-1 mRNA levels and the MIF-induced cell survival (Supplementary Figure 5D-F) . In addition, CLL cells were incubated with a commercially available antagonistic anti-CD84 Ab (CD84.1.21) that recognizes the extracellular domain fragment of CD84, and survival was followed over time. Similar to the results with the supernatant of the hybridoma F8, incubation with the blocking antibody reduced Bcl- 2 mRNA levels (Figure 6a ), Bcl-2 protein levels ( Figure 6b ) and cell survival (Figures 6c and d) . We then determined whether blocking CD84 activity might have a therapeutic effect, regulating the survival of CLL cells in vivo. It was shown recently in a CLL xenograft model that the highest absolute numbers of recovered human cells were consistently observed in murine spleen, especially when the tumor cells were administered intravenously (i.v.), 33 whereas cells could not be detected in the lymph nodes. 34 Therefore, CLL survival following CD84 blockade was analyzed in the spleen. CLL cells were stained with carboxyfluorescein succinimidylester (CFSE) and injected i.v. into C57BL/6 mice to allow their homing to the spleen, an event that was shown to be almost integrin independent. 10,34 After 1 h, mice were injected with the anti-CD84 blocking antibody or an isotype control antibody, and after an additional 3 h, CLL numbers in the spleen and BM were analyzed by fluorescence-activated cell sorting (FACS). As shown in Figure 6e , blocking CD84 resulted in a significant reduction in the CLL cell population. Similar numbers of CLL cells were detected in the BM of anti-CD84-treated and nontreated mice, suggesting that homing to this compartment is not affected (Figure 6e ). This result suggests that it is much more difficult to induce cell death in the BM compartment. This might result from the lack of accessibility of the CLL cells in the BM or from the niches in this compartment that support CLL survival. Furthermore, to exclude the possibility that the reduced number of cells resulted from interaction of the antagonistic anti-CD84 with residual natural killer (NK) cells, fluorescently labeled CLL cells were injected into RAG2 À / À gc À / À mice. In addition to the absence of T and B cells due to knockout of the RAG2 gene, these mice lack the common cytokine receptor g chain (gc), which is essential for NK cell development and for export of NKT cells from the thymus. 35 Blocking CD84 resulted in a similar reduction in CLL cells collected from the spleen (Figure 6f ).
As CLL arrival to the spleen is considered an integrinindependent process, 34 the reduction in the CLL cells recovered from the spleen is likely due to decreased cell survival, and not impaired migration to this organ. Thus, CD84 has a significant in vivo effect in regulating CLL survival, which does not result from the involvement of residual murine NK cells.
Finally, we analyzed CD84 mRNA and protein levels in samples derived from an on-going clinical trial (Clinicaltrials.gov. NCT00868478), in which human subjects were treated with milatuzumab (hLL1), with repeat infusion of the moAb over several weeks. A decrease in CD84 mRNA levels was observed in cells from three patients treated with milatuzumab ( Figure 7a ). This downregulation was correlated with reduction of Bcl-2 ( Figure 7b ) and Mcl-1 (Figure 7c ) message. Furthermore, blocking CD74 resulted in a significant reduction of CD84 and Bcl-2 protein levels ( Figure 7d) . Interestingly, following cessation of milatuzumab treatment, there was a rapid rise in CD84 (Figure 7e ), Bcl-2 ( Figure 7f ) and Mcl-1 (Figure 7g ) expression, with a decrease upon resuming treatment, correlating with the observed clinical response. This result directly demonstrates that blocking CD74 activity in vivo results in downregulation of CD84 expression and cell death.
DISCUSSION
CLL is a malignant disease characterized by the progressive accumulation of small mature B-lymphocytes in peripheral blood, BM and secondary lymphoid organs. Despite insights into their cell survival pathways and steady improvements in patient outcomes over the past decade, there is still a need for a more targeted and curative therapy in CLL.
We showed previously that CLL cells express high levels of CD74, which upon stimulation with its natural ligand, MIF, initiates a signaling cascade leading to cell survival. 9, 10 Both MIF and CD74 have been associated with tumor progression. It was reported that MIF mRNA is overexpressed in various tumors, and MIF also has been associated with the growth of malignant cells. MIF was shown to be overexpressed in solid tumors, 36 and it is frequently overexpressed in primary breast cancer tissues where it plays a role in tumor-stroma interactions. 37 MIF also is associated with tumor growth and tumor-associated angiogenesis in a murine colon cancer cell line. 38 In addition, anti-MIF antibody has been shown to suppress tumor growth in different tumor models. 39, 40 The overexpression of CD74, the cell surface receptor for MIF, also is a characteristic of various cancers [41] [42] [43] [44] [45] [46] including CLL. 47, 48 CD74 expression in many cancers may serve as a prognostic factor, with higher relative expression of CD74 being associated with tumor progression. 49 MIF is secreted constantly from virtually all type of cells, therefore, CLL cells are stimulated by this chemokine in all compartments.
In the current study, we searched for novel MIF/CD74 target genes in CLL cells. We show that the expression of the SLAM family member, CD84, whose expression levels are significantly elevated on CLL cells from the early stages of the disease, is specifically regulated by MIF and its receptor, CD74. Moreover, as . hLL1 administration to human subjects results in downregulation of CD84, Bcl-2 and Mcl-2 mRNA levels. CLL patients were treated with hLL1 as part of a clinical trial, as described in Methods. (a-d) Blood was taken from three patients before (untreated) and after treatment (hLL1). CLL cells were isolated, and RNA was purified. qRT-PCR was performed using primers for CD84, Bcl-2, Mcl-1 or RP-2. Results are expressed as fold change in CD84, Bcl-2 or Mcl-1 expression; expression levels in cells from pretreatment samples were defined as 1. The graphs summarize the results of the three CLL patients. (d) Blood was taken from two patients before (untreated) and after treatment (hLL1). CD84 and Bcl-2 protein levels were analyzed by FACS after staining with appropriate antibodies. (e-g) Human subjects were treated with hLL1 with repeat injections over several weeks; then, the treatment was discontinued for several weeks and subsequently resumed. Blood was taken from each patient before treatment (untreated), after the first round of treatment (hLL1), upon stopping treatment (stop) and following resumption of treatment (resume); cells were isolated and RNA was purified. qRT-PCR was performed using primers for CD84, Bcl-2, Mcl-1 or RP-2. Results are expressed as fold change in CD84, Bcl-2 or Mcl-1 expression; expression levels in pretreatment cells were defined as 1. The graphs summarize results from a representative CLL patient. Each PCR was repeated three times and the average result is presented.
survival. Induction of Akt phosphorylation peaked 1 min following CD84 activation, similar to Akt phosphorylation following BCR engagement. 30 Thus, CD84 is a pro-survival molecule. Interestingly, in an on-going clinical trial (Clinicaltrials.gov. NCT00868478), in which human subjects were treated with milatuzumab (hLL1), a significant decrease in CD84 mRNA levels and reduction of Bcl-2 and Mcl-1 message were observed, which were restored upon interruption of therapy.
Homophilic interactions of SLAM family members lead to clustering and activation of the receptor. 32, 50 It was recently shown that CD84 is involved in T cell-B cell contact, optimal T follicular helper function and germinal center formation in vivo. Moreover, both CD84 and another SLAM member, Ly108, mediate T cell adhesion and participate in stable T cell-B cell interactions. 24 In the BM and lymph nodes, CLL cells interact with a variety of accessory and bystander cells that support CLL cell survival and are believed to promote resistance to therapy. It is plausible that these interactions are CD84 dependent, as well. It will be important therefore to analyze the accessory cells that are involved in the CD84-dependent interaction.
The clinical potential of monoclonal antibodies in oncology has been fully realized only recently. The use of anti-CD20 monoclonal antibody (Rituximab) in CLL set the stage for the development of novel agents to target B cell malignancies. Anti-CD52 (Alemtuzumab) has also shown remarkable activity in patients with CLL, and a series of additional monoclonal antibodies with specificity against a variety of antigens on the surface of B cells (CD22,23,40,70 HLA and others) are currently undergoing evaluation.
Our results show that inhibition of CD84 leads to a reduced Bcl-2 expression and elevation of CLL cell death in vitro. In addition, the significant effect of in vivo treatment with anti-CD84 suggests a novel target and new potential modalities for the therapy of CLL. In conclusion, our data show that overexpression of CD84 in CLL is an important survival mechanism that appears to be an early event in the pathogenesis of the disease. These findings could pave the way toward unique therapeutic strategies aimed at interrupting this survival pathway.
MATERIALS AND METHODS
Patient population
B lymphocytes obtained from the peripheral blood of both healthy subjects (control) and CLL patients at varying stages of the disease were provided by the Hematology Institute of Kaplan Medical Center and the Sourasky Medical Center in compliance with the institutional review boards of the hospitals, as previously described. 51, 52 The diagnosis of CLL was based on standard criteria. 53 Patients were staged according to the Rai staging system 54 (Supplementary Table 1 ).
Reagents MIF: Recombinant human MIF was purified from an expression system as previously described, and the contaminating endotoxin removed by C8 chromatography. 55 The final endotoxin concentration was o0.032 EU mg À 1 MIF. hLL1 antibody: The hLL1 anti-CD74 mAb (IMMU-115; milatuzumab) was provided by Immunomedics (Morris Plains, NJ, USA). Development and properties of hLL1 were described previously. 12, 56 Cell purification B-lymphocytes were purified from whole blood using a RosettSep antibody cocktail (StemCel, Vancouver, BC, Canada), as previously described. 9, 51 Stimulation and blocking of cells MIF stimulation was performed as previously described.
9,10 CD84 stimulation was performed as described previously. 22 Briefly, 1 Â 10 7 CLL cells were suspended in the presence of 0.25 mg anit-CD84 antibody (152-1D5, Abcam, Cambridge, UK) followed by 0.5 mg anti-Fab (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) or an IgG isotype control antibody (MOPC-21 BioLegend, San Diego, CA, USA). CD84 blocking was performed as previously described.
14 Briefly, 1 Â 10 7 CLL cells were incubated in the presence of 2.5 mg of anti-CD84 blocking antibody (CD84.1.2; BioLegend) at 37 1C for 18-24 h.
Cell lysis
Lysis of cells was performed as previously described. 57 For detection of phosphorylated proteins, cells were lysed as previously described. 6 
DNA chip arrays
The Affymetrix genechip expression analysis system was used for differential expression analysis, as previously described. 58 Immunoprecipitation and western blot analysis Immunoprecipitation-Protein-G Sepharose beads (Pharmacia, New York, NY, USA) were conjugated to anti-EAT-2 (N-14; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CD84 (152-1D5; Santa Cruz Biotechnology) for 2 h at 4 1C. Beads were added to the cell lysates, and tyr(p) proteins were immunoprecipitated overnight.
Immunoprecipitates or lysates were separated by 8-12% SDSpolyacrylamide gel electrophoresis. The proteins were then transferred onto a nitrocellulose membrane and probed with various antibodies (Supplementary Table 2 ) followed by horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies (Jackson ImmunoResearch Laboratories). The membrane was then stripped and reprobed with anti-tubulin antibody (Sigma), followed by peroxidase-conjugated anti-mouse (Jackson ImmunoResearch Laboratories).
Flow cytometry
Staining of CLL cells was performed as described previously. 51 The following antibodies were used: anti-CD84 (152-1D5 Santa Cruz Biotechnology), CD19 (IQP-525R IQProducts), CD5 (IQP-103F IQProducts), followed by phycoerythrin (PE), fluorescein isothiocyanate (FITC) and allophycocyanin (APC) anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories).
Intracellular staining of Bcl-2
Permeabilization and staining were performed using commercial reagents (eBioscience, San Diego, CA, USA, IC fixation buffer, Permeabilization buffer). To this end, 1 Â 10 6 CLL cells were washed once with phosphatebuffered saline, followed by fixation and permeabilization according to the manufacturer's instructions. Cells were then incubated with FITC-conjugated anti-Human Bcl-2 (eBioscience, CloneBcl-2/100) or isotope control (eBioscience, mouse IgG1K) antibodies for 15 min at room temperature. Cells were washed twice with permeabilization buffer, and analyzed by flow cytometry.
Annexin and PI staining
Cells were washed and stained with Annexin (BD Biosciences), and PI (25 mg/ml; Sigma) was added for 15 min at room temperature. The extent of Annexin þ PI staining was analyzed by FACS. The line between the positive and the negative populations in these staining experiments was placed based on the unstained population.
Magic red apoptosis detection kit
Cells were incubated with Magic Red (Immunochemistry Technology, Bloomington, MN, USA) according to the manufacturer's instructions, at 37 1C for 1 h. Magic Red staining then was measured by FACS analysis. The line between the positive and the negative populations in these staining experiments was placed based on the unstained population.
CD74 stimulation and blocking MIF stimulation and blocking was performed as previously described. 6, 7, 9 RNA isolation and reverse transcription Total RNA was isolated as previously described. 9, 10 Primers sequences can be found in Supplementary Table 2. CD84 is a survival receptor I Binsky-Ehrenreich et al
Real-time reverse transcription (RT)-PCR analysis mRNA levels were analyzed by quantitative real-time RT-PCR as previously described. 8 PCR reactions were performed in duplicates, as previously described. 59 Primer sequences can be found in Supplementary Table 2 . Rp-2 (retinitis pigemntosa) served as a house keeping gene.
Constructs
The ECD-CD84 (25-685 bp) constructs in the pEF4/Myc-His (Invitrogen) vector was designed as previously described. 60 Primers used for cloning: BamH1CD84: 5 0 -CGTCGGATCCATGGCTCAGC ACCAC-3 0 ; EcoR1CD84: 5 0 -TAGCGAATTCACGGAAGCCCATTGC-3 0 .
Transfection and protein expression of secreted CD84-ECD HEK 293T cells were transfected as previously described. 61 The conditioned medium was collected after 24 h, and protein purification from conditioned medium was performed using fast protein liquid chromatography (FPLC). After binding of the protein to the Ni2 þ column, the column was washed and eluted with high concentrations of imidazole, which competes with the His6-tag and displaces the protein.
Hybridoma protocol
Mice were immunized with CD84-ECD over a period of 5 months. Following a positive ELISA, the spleens were removed and the lymphocytes isolated and fused with NSO cells. Hybridomas were selected and their supernatants were analyzed for recognition of CD84-ECD using an ELISA assay. 62 Small interfering RNA transfection and analysis CLL cells were transfected with small interfering RNA as previously described. 10 si LacZ: 5 0 -AAGTGACCAGCGAATACCTGT-3 0 . si Bcl2:: Dharmacon ON-TARGETplus SMARTpool Human BCL2; NM_ 000633; NM_00065.
si CD84: Dharmacon ON-TARGETplus SMARTpool Human CD84; NM_003874.
Constructs
The full-length human CD84 (25-1010 bp) and the ECD-CD84 (25-685 bp) constructs in the pEF4/Myc-His vector (Invitrogen) were designed as previously described. 60 Primers used for cloning: BamH1CD84: 5 0 -CGTCGGATCCATGGCTCAGCACCAC-3 0 . EcoR1CD84: 5 0 -TA GCGAATTCACGGAAGCCCATTGC-3 0 .
Site-directed mutagenesis
The Stratagene QuickChange Site-directed Mutagenesis Kit was used, following the manufacturer's instructions. The following tyrosine mutants were derived from the CD84-full construct:
(1) Y262F (2) Y262F, Y299F In vivo cell tracking CLL cells were labeled with 5 mM CFSE (Molecular Probes, Grand Island, NY, USA) for 15 min at room temperature. CFSE labeling had no effect on cell survival throughout the experiment. Following labeling, 1 Â 10 7 cells were i.v. injected into control C57BL/6, RAG2 mice, and mice deficient in the common cytokine receptor g chain (RAG2 À / À /gc À / À 35 ). After 1 h, anti-CD84 (CD84.1.21, BioLegend) or an isotype control (BioLegend) were i.v. injected. The number of CLL cells in the spleen was determined 3 h later by FACS analysis of isolated spleens.
Clinical trial protocol
Details can be found in http://clinicaltrials.gov/ct2/show/NCT00868478? term=milatuzumab&rank=2.
Statistical analysis
Statistical analysis was performed using SPSS, as described previously. 9 
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